Pre-travel Health Advice for Patients With Cardiovascular Disease

Chee Hwui Liew1,2,3, Gerard Thomas Flaherty1,3,4*

1School of Medicine, National University of Ireland Galway, Galway, Ireland
2School of Medicine, Trinity College Dublin, Dublin, Ireland
3National Institute for Prevention and Cardiovascular Health, Galway, Ireland
4School of Medicine, International Medical University, Kuala Lumpur, Malaysia

Corresponding Author: Gerard Thomas Flaherty, MD, Professor, School of Medicine, National University of Ireland Galway, Galway, Ireland. Tel: +353-91495469, Email: gerard.flaherty@nuigalway.ie

Received July 8, 2019; Accepted July 8, 2019; Online Published August 31, 2019

Abstract
Cardiovascular disease (CVD) is the leading cause of death among international travellers. Practitioner knowledge of the effects of CVD on international travel is imperative in order to promote a healthy travel experience. This review aimed to explore the available literature on this topic. The PubMed database was accessed to source relevant literature using combinations of relevant keywords as search terms. Articles were restricted to those published in the English language through March 2019. Of 1726 article records retrieved, 73 relevant papers were examined carefully. The results of this narrative review are related to multiple aspects of CVD and travel. The pre-travel consultation should address issues regarding vaccinations, travel insurance, anticoagulation, and medical devices. Additional vaccines to be discussed include influenza, pneumococcal, and hepatitis B. Patients with CVD should be advised of the need to carry a copy of their ECG, prescription(s), and pacemaker manufacturer’s card. Knowledge of the location overseas of automated external defibrillators and awareness of health risks associated with strenuous adventure activities are important for CVD travellers. Medical tourism for patients with CVD is briefly considered. Space tourism is an emerging category of extreme international travel that requires specialized pre-travel preparation. This narrative review article highlights the gaps in the travel medicine literature in relation to CVD. A strong evidence base for most recommendations is lacking. Future scholarly efforts are warranted to facilitate more robust travel recommendations for CVD patients. No qualitative studies to date have described the experiences of international travellers with CVD.

Keywords: Cardiovascular Disease, Travel, Altitude, Medical Tourism, Medical Devices

Introduction

International tourism, as a global economic sector, has experienced significant growth in recent decades. According to the World Tourism Organization, there were over 1.3 billion international tourist arrivals in 2017, and this figure is expected to reach 1.8 billion by 2030.1 Parallel to the growth in international travel is an increase in the incidence and prevalence of cardiovascular disease (CVD), which remains the leading cause of death globally.2 Importantly, the same phenomenon is also present among international travellers.3 Cardiac-related diseases commonly contribute to in-flight medical emergencies4-5; hence a sound knowledge of the relationship between CVD and international travel is of fundamental importance.

The effect of air travel on the cardiovascular system has been well studied.6 However, the extent to which CVD affects the experiences of international travellers has not previously been determined. A previous qualitative study examined the experiences of obese patients during international travel.7 Most patients perceived a health benefit to travel. Despite this, obesity was generally regarded as a considerable barrier to international travel. People with CVD may also find their travel experiences stressful owing to various difficulties related to their disease and its pharmacotherapy. These could range from issues encountered in the airport to limited participation in activities abroad owing to the fear of unpredictable medical events. The influence of travel on decompensation of pre-existing CVD has not been previously reviewed. Thus, there is a lack of guidance for travel medicine practitioners and specialist cardiologists when confronted...
Methods
Search Strategy
The PubMed database was accessed to source relevant literature. Combinations of the following keywords were used as search terms: ‘cardiovascular’, ‘cardiac’, ‘heart’, ‘travel’, ‘travelling’, ‘air travel’, ‘congenital heart disease’, ‘stroke’, ‘cardiac device’, ‘airport’, ‘pacemaker’, ‘automated external defibrillator’, ‘microgravity’, ‘sport’, ‘adventure activity’, ‘adventure sports’, ‘diving’, ‘medical tourism’, ‘travel insurance’, ‘travellers’, ‘abroad’, ‘airplane’, ‘heart transplant’, and ‘medication’. Articles were restricted to those published in the English language through March 2019. Priority was given to articles published in the past 5 years. Articles that were not accessible in full text were excluded. Reference lists of the articles identified were screened for additional sources. The grey literature was also searched for relevant material (Figure 1).

Results
Cardiovascular Conditions
Heart Failure
Current recommendations based on a survey by Ingle et al state that air travel is generally safe in passengers with stable chronic heart failure (CHF) without the necessity of changes in medication or symptoms. Their study involved 464 CHF patients. Notably, the travel destinations, hence the time spent on airplanes, were varied. This may impact the extent of hypoxia experienced during the journey by air. Another study illustrated that CHF symptoms did not worsen with reduced inspired oxygen in the cabin environment. For travellers with more severe CHF, e.g., New York Heart Association (NYHA) classification III or IV, oxygen supplementation is recommended. The use of in-flight oxygen supplementation may be an unpleasant experience for these travellers.

Coronary Heart Disease
Chest pain, or angina, associated with coronary heart disease (CHD) frequently precipitates flight diversions. At sea level, severe atherosclerotic lesions diminish oxygen availability in patients with CHD. This becomes crucial during air travel, as the angina threshold is often reduced due to physiologic changes. A comprehensive review by Smith et al outlined the suitability of air travel in patients with CHD. Their recommendations were mainly based on observational studies as well as analyses of in-flight medical emergencies. Notably, the data only involved air travel after uncomplicated myocardial infarction (MI). There may be nuances in outcomes for travellers with MI complicated by reduced ventricular function or arrhythmias.

Stroke
Cerebrovascular accident (CVA) or stroke patients may find...
it challenging to pursue international travel due to impaired mobility. A comprehensive recommendation for air travellers with stroke is lacking. A review by Barros et al illustrated this significant gap in the literature.\textsuperscript{13} The International Air Transport Association states that air travel is permissible in stroke patients five to fourteen days post-event.\textsuperscript{14} Additionally, the use of in-flight supplemental oxygen is also recommended for these travellers. In contrast to the dearth of literature on air travel in stroke patients, there is abundant literature that describes in-flight and post-flight stroke incidence\textsuperscript{15-17} as well as repatriation due to CVA abroad.\textsuperscript{18,19}

**Congenital Heart Disease**

The literature on congenital heart disease (CGHD) and air travel is limited. Harinck et al reported that it was generally safe to fly with CGHD.\textsuperscript{20} However, their study was underpowered with only twelve patients. Additionally, the risk was not stratified based on NYHA classification. More recently, a systematic review of eleven studies supported the recommendations from the Harinck study.\textsuperscript{21} The review only included observational studies; importantly, patients with cystic fibrosis were also present. This entailed a more complex analysis of the included studies.

**High Altitude Travel**

As mountain activities have evolved, e.g., skiing and snowboarding, the pursuance of high-altitude tourism (HAT) has become increasingly popular.\textsuperscript{22} High-altitude illnesses (HAI) secondary to hypoxia at decreased barometric pressure are well established. It is beyond the scope of this review to discuss HAI in detail.\textsuperscript{23} Pulmonary hypertension at high altitude has also been described.\textsuperscript{24,25} With these in mind, it is important for high-altitude travellers with CVD to be mindful of appropriate pre-travel preparations.\textsuperscript{26}

High altitude affects underlying CVD in various ways, e.g., altered physiologic parameters and medication doses (Table 1). A guideline by the Medical Commission of International Climbing and Mountaineering Federations may be a valuable resource in pre-travel consultations.\textsuperscript{28} Although comprehensive, the data reported was based solely on observational studies. Notably, recommendations for travellers with valvular heart disease or heart transplant were more limited. Pre-travel submaximal exercise testing has been proposed to have good predictive value, though its effectiveness requires validation in larger studies.\textsuperscript{29}

**Activities, Sports, and Climate**

The pursuit of recreational activities during international travel is highly desirable. However, travellers with CVD may restrict themselves due to health concerns. A retrospective study in Austria showed that MI usually occurred within the first two days of initiating physical activities at travel destinations.\textsuperscript{30} Notably, the study had only 110 patients with a mean age of 60 years. The same phenomenon may not be evident in different age groups. Adventure water sports abroad have grown in popularity in the last century; accordingly, a pre-travel medical evaluation is strongly recommended for these tourists.\textsuperscript{31} Currently, no guidelines specific to CVD patients in this regard are available. However, there is a wealth of literature in relation to diving. A cross-sectional study showed that CVD was highly prevalent among divers.\textsuperscript{32} Possible long-term cardiovascular effects from diving have been identified based on a study that compared the cardiovascular profiles of former divers and non-divers.\textsuperscript{33} It must be kept in mind that former divers and travellers who dive leisurely may not be directly comparable, as the latter tend to dive for a shorter period of time. Additionally, that study did not examine short-term or immediate cardiovascular outcomes, e.g., occurrence of MI during diving. Nonetheless, cold water immersion from diving has been associated with cardiac arrhythmias, and thus a heightened awareness among CVD travellers is warranted.\textsuperscript{34}

Extremes of climate can be significant for adventure

<table>
<thead>
<tr>
<th>Issue</th>
<th>Health Effects and Clinical Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular changes</strong></td>
<td>Small increase in systemic blood pressure</td>
</tr>
<tr>
<td></td>
<td>Increased heart rate and cardiac output through sympathetic vasoconstriction</td>
</tr>
<tr>
<td></td>
<td>Increased risk of ventricular tachyarrhythmias</td>
</tr>
<tr>
<td><strong>Medications</strong></td>
<td>Adjustments in antihypertensive medication doses may be required.</td>
</tr>
<tr>
<td></td>
<td>Dehydration from diuretics may be compounded.</td>
</tr>
<tr>
<td></td>
<td>Nifedipine prophylaxis for asymptomatic CHD patients with pulmonary hypertension may be required.</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>Altitude travel contraindicated for six months following MI</td>
</tr>
<tr>
<td></td>
<td>Altitude exposure contraindicated in symptomatic heart failure</td>
</tr>
<tr>
<td></td>
<td>No evidence for increased risk of CABG graft closure or PTCA stent re-stenosis</td>
</tr>
<tr>
<td></td>
<td>Physical exertion should be avoided during acclimatization</td>
</tr>
<tr>
<td><strong>General precautions</strong></td>
<td>Patients with stable CHD should tolerate travel up to 2500 m.</td>
</tr>
<tr>
<td></td>
<td>Respiratory alkalosis, cold and sympathetic activation may reduce myocardial perfusion.</td>
</tr>
<tr>
<td></td>
<td>Lower angina threshold</td>
</tr>
<tr>
<td></td>
<td>Congenital heart disease patients are more susceptible to HAPE.</td>
</tr>
</tbody>
</table>

CABG: coronary artery bypass grafting; PTCA: percutaneous transluminal coronary angiography; HAPE: high altitude pulmonary oedema; CHD: coronary heart disease.
travellers with CVD. Low temperature has been associated with MI. Conversely, CVD travellers may be more vulnerable to heat stress, especially those on beta blockers and diuretics, due to autonomic dysregulation and excessive fluid loss, respectively. In particular, hot temperatures have received considerable attention with regard to increased cardiovascular mortality in patients with established CVD.

Vaccinations
Apart from the recommended travel vaccinations, additional vaccines may be recommended in CVD patients. A landmark study that systematically reviewed eight randomized controlled trials (RCTs) of 12 000 patients highlighted the benefits of influenza vaccine in CVD. Notably, not all patients in the trials had established CHD; some belonged to the category of primary prevention patients. In contrast, no RCTs have evaluated the benefits of pneumococcal vaccine in CVD, although retrospective studies have shown advantages. A strong evidence base for hepatitis B vaccine in CVD patients is lacking, despite being generally recommended in this traveller group who may be at increased risk of nosocomial transmission of hepatitis B. In fact, a recent study showed that hepatitis B infection did not increase CHD risk. However, that study only involved cohort and case-control studies. Table 2 summarizes the current recommendations for influenza and pneumococcal vaccinations in the most recent European Society of Cardiology (ESC) guidelines. Importantly, the level of recommendation varies according to individual published guidelines.

Travel Insurance
The importance of travel insurance (hereafter termed ‘insurance’) in CVD patients has previously been highlighted. However, patients may face obstacles when obtaining insurance. In particular, people with CGHD are often denied coverage. This leads to the practice of not declaring their condition in order to become insurance-eligible. Insurance is crucial as cardiac emergencies are among the most common conditions for aeromedical evacuation which is generally covered by insurance. Therefore, it is imperative for travellers with any cardiac condition to be medically covered in order to access medical care abroad if required. Indeed, emergency medical assistance service (EMAS) was perceived to be fundamental by international travellers based on a recent survey. The study did not exclusively include travellers with CVD. Importantly, about 30% of travellers were not aware of EMAS abroad.

Medical Tourism
In recent years, medical tourism has proliferated such that there are now dedicated commercial agencies offering medical tourism packages to clients. It is estimated that 1.9 million travellers will seek medical care outside the United States in 2019. Cardiac surgery, including coronary artery bypass graft surgery, is one of the most common procedures sought by medical tourists abroad. Several Asian countries, including Thailand and India, are well-known medical tourism destinations for cardiac surgery, mainly due to lower costs. However, a caveat revolves around the quality of care provided to travellers who have received cardiac surgery abroad, and prospective medical tourists should be aware of these quality concerns.

Anticoagulation
As international travel expands, physicians’ knowledge of the agents available for anticoagulation in CVD patients is essential. New oral anticoagulants (NOACs) like rivaroxaban and dabigatran are now in widespread use. NOACs have increased in popularity due to reduced pharmacologic interactions and the lack of routine international normalized ratio (INR) monitoring during international travel. A potential worry is the bleeding risk associated with NOACs. A landmark study of 72 000 patients demonstrated that NOACs had similar bleeding event rates as warfarin, with a favorable risk-benefit profile. As NOACs are relatively new, most anticoagulated travellers will be taking warfarin. No previous study has examined their difficulty in monitoring INR overseas. Anticoagulated individuals may be assumed to bleed more when receiving pre-travel vaccinations; however, an RCT in Spain involving 229 patients showed that intramuscular injection of the influenza vaccine did not result in more bleeding than the subcutaneous route.

Medical Devices and Automated External Defibrillators
Literature on implanted cardiac devices in relation to international travel is sparse. These devices, like permanent pacemakers and implanted cardioverter-defibrillators, may add complexity when passing through airport security checkpoints. The fear of electromagnetic interference with these devices may concern some travellers. Modern devices are well shielded, however, and seem to be unaffected by both metal detector gates and hand-held metal detectors. However, if concerns arise, a pat down manual search may be considered. Prior communication with the airport authority is recommended. A device card and physician letter should

Table 2. Graded Recommendations for Influenza And Pneumococcal Vaccination in the Current Guidelines of the European Society of Cardiology

<table>
<thead>
<tr>
<th>Type of Guidelines</th>
<th>Year of Publication</th>
<th>Recommended Vaccination</th>
<th>Strength of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of cardiovascular diseases</td>
<td>2016</td>
<td>Influenza</td>
<td>Class IIIb/Level C</td>
</tr>
<tr>
<td>Acute and chronic heart failure – prevention and treatment</td>
<td>2016</td>
<td>Influenza and pneumococcal</td>
<td>According to local guidelines</td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>2015</td>
<td>Influenza and pneumococcal</td>
<td>Class I/Level C</td>
</tr>
<tr>
<td>Stable coronary artery disease</td>
<td>2013</td>
<td>Influenza</td>
<td>Class I/Level C</td>
</tr>
</tbody>
</table>
also be carried by the traveller.27

Knowledge of the location of automated external defibrillators (AEDs) among international travellers is inadequate based on an airport survey.62 Nonetheless, locations of AEDs should be more publicly accessible to facilitate their retrieval when needed63-65; this is particularly crucial if the traveller is not familiar with the surroundings abroad. Technological inventions, e.g., a verified mobile AED map66 and medical drones,67 may potentially serve as useful aids for international travellers in the future.

**Microgravity in Space Tourism**

Space tourism is no longer a fantasy, with the first “space tourist”, Dennis Tito, spending a week on board the International Space Station in 2001.68 The presence of a dedicated society as well as research plans herald a potential growth in this sector.69 The cardiovascular effects of microgravity in space tourism have been identified, e.g. altered orthostatic tolerance and increased risk of cardiac arrhythmia.70,71 Accordingly, it would be ideal for travel medicine physicians, cardiologists, and general practitioners to have a basic knowledge of the health risks associated with space tourism. In addition, space travellers with CVD should obtain appropriate pre-travel advice. Use of an artificial gravity system has been shown to alleviate some of the cardiovascular effects;72 perhaps this will augment the safety features in future spacecrafts. It remains to be seen what adaptations will have to be made for cardiopulmonary resuscitation to make it suitable in the microgravity environment.73 The travel medicine physician of the near future may require sufficient knowledge of space physiology and the cardiovascular effects of microgravity to provide reasonable counsel to patients at risk of coronary events during commercial space flights.

**Conclusion and Recommendations for Future Research**

The available literature suggests that international travel is generally safe in stable, well-prepared CVD patients. The pursuit of high-altitude tourism, space tourism, and terrestrial and aquatic adventure activities may not be suitable for all CVD travellers owing to the potentially heightened health risks involved. Adequate pre-travel consultations would address issues regarding vaccinations, travel insurance, anticoagulation, medical tourism, and medical devices. Knowledge of AEDs among CVD travellers is important, yet lacking. In addition, knowledge of space tourism among healthcare providers would be desirable.

This review has highlighted both the paucity of literature in relation to CVD and international travel as well as the gaps in the available literature. Future high-quality research with larger sample sizes is warranted to generate robust travel recommendations for CVD patients, in particular, recommendations for those with stroke and congenital heart disease. The safety of adventure water sports in CVD patients also requires validation. Solutions for difficulties in obtaining travel insurance should be explored to ensure optimal accessibility of emergency medical assistance abroad, if needed. Notably, no literature has described the international travel experiences of CVD patients. We are currently undertaking a qualitative study on this topic. It is hoped that the findings from this study will reduce the travel health risk of CVD patients, contribute to better travel recommendations, and importantly, foster an optimal and enjoyable travel experience for this vulnerable group of travellers.

**Authors’ Contributions**

GTF was responsible for study conception. CHL and GTF designed the study. CHL conducted the literature search and prepared the first draft of the manuscript. GTF edited the draft manuscript for significant intellectual content. Both authors read and approved the final version of the manuscript.

**Conflict of Interest Disclosures**

The authors declare that they have no conflicts of interest.

**Ethical Approval**

Not applicable.

**Funding/Support**

None.

**References**

Liew and Flaherty


